tiprankstipranks
AbCellera Biologics (ABCL)
NASDAQ:ABCL

AbCellera Biologics (ABCL) Ownership - Who Owns AbCellera Biologics?

1,220 Followers

AbCellera Biologics (ABCL) Ownership Overview

47.69%4.61%28.86%18.83%
47.69% Insiders
28.86% Other Institutional Investors
18.83% Public Companies and Individual Investors
The ownership structure of AbCellera Biologics (ABCL) stock is a mix of institutional, retail and individual investors. Approximately 33.47% of the company’s stock is owned by Institutional Investors, 47.69% is owned by Insiders and 18.83% is owned by Public Companies and Individual Investors.
The ownership structure of AbCellera Biologics (ABCL) stock is a mix of institutional, retail and individual investors. Approximately 33.47% of the company’s stock is owned by Institutional Investors, 47.69% is owned by Insiders and 18.83% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 27, 2023
Carl L. G. Hansen
Ceo,director, >10% Owner
Bought$151538
Nov 08, 2023Bought$137400
Sep 26, 2023Bought$98200
Sep 14, 2023
Veronique Lecault
Coo,director
Bought$103800

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2023Sold$429146
Dec 31, 2023Bought$130814689

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
22,909,753.00Institution7.82%111,570,497.11
5,480,000.00Institution1.87%26,687,600.00
2,565,729.00Institution0.88%12,495,100.23
1,938,013.00Institution0.66%9,438,123.31
841,882.00Institution0.29%4,099,965.34
835,455.00Institution0.29%4,068,665.85
747,114.00Institution0.26%3,638,445.18
659,750.00Institution0.23%3,212,982.50
606,663.00Institution0.21%2,954,448.81
497,264.00Institution0.17%2,421,675.68

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
5,480,000.00Institution1.87%26,687,600.00
1,938,013.00Institution0.66%9,438,123.31
841,882.00Institution0.29%4,099,965.34
835,455.00Institution0.29%4,068,665.85
747,114.00Institution0.26%3,638,445.18
606,663.00Institution0.21%2,954,448.81
497,264.00Institution0.17%2,421,675.68
472,389.00Institution0.16%2,300,534.43
436,723.00Institution0.15%2,126,841.01
329,656.00Institution0.11%1,605,424.72

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,496,948.00Institution0.51%7,290,136.76
336,511.00Institution0.11%1,632,078.35
133,474.00Institution0.05%872,885.26
148,291.00Institution0.05%719,211.35
148,215.00Institution0.05%718,842.75
139,336.00Institution0.05%675,779.60
133,301.00Institution0.05%646,509.85
112,981.00Institution0.04%547,957.85
88,494.00Institution0.03%505,300.74
68,068.00Institution0.02%330,129.80

FAQ

Who Owns AbCellera Biologics (ABCL)?
According to the latest TipRanks data, approximately 28.86% of the company's stock is held by institutional investors, 47.69% is held by insiders, and 18.83% is held by retail investors.
    What percentage of AbCellera Biologics (ABCL) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 28.86% of AbCellera Biologics (ABCL) stock is held by institutional investors.
      What percentage of AbCellera Biologics (ABCL) stock is held by retail investors?
      According to the latest TipRanks data, approximately 18.83% of AbCellera Biologics (ABCL) stock is held by retail investors.
        Who owns the most shares of AbCellera Biologics (ABCL)?
        Felix Baker owns the most shares of AbCellera Biologics (ABCL).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis